Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1979 1
1980 1
1982 1
1983 2
1984 5
1985 3
1986 1
1987 1
1988 2
1989 5
1990 2
1991 4
1992 3
1993 3
1994 4
1995 3
1996 2
1997 3
1998 9
1999 7
2000 6
2001 9
2002 9
2003 9
2004 8
2005 10
2006 5
2007 8
2008 8
2009 9
2010 9
2011 15
2012 16
2013 21
2014 22
2015 18
2016 32
2017 39
2018 32
2019 40
2020 50
2021 57
2022 47
2023 37
2024 21

Text availability

Article attribute

Article type

Publication date

Search Results

530 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Locally Advanced Cutaneous Melanoma"
Page 1
Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial.
Meric-Bernstam F, Makker V, Oaknin A, Oh DY, Banerjee S, González-Martín A, Jung KH, Ługowska I, Manso L, Manzano A, Melichar B, Siena S, Stroyakovskiy D, Fielding A, Ma Y, Puvvada S, Shire N, Lee JY. Meric-Bernstam F, et al. J Clin Oncol. 2024 Jan 1;42(1):47-58. doi: 10.1200/JCO.23.02005. Epub 2023 Oct 23. J Clin Oncol. 2024. PMID: 37870536 Free PMC article. Clinical Trial.
METHODS: This open-label phase II study evaluated T-DXd (5.4 mg/kg once every 3 weeks) for HER2-expressing (immunohistochemistry [IHC] 3+/2+ by local or central testing) locally advanced or metastatic disease after 1 systemic treatment or without alternative …
METHODS: This open-label phase II study evaluated T-DXd (5.4 mg/kg once every 3 weeks) for HER2-expressing (immunohistochemistry [IHC] 3+/2+ …
Colorectal cancer immunotherapy-Recent progress and future directions.
Zhao W, Jin L, Chen P, Li D, Gao W, Dong G. Zhao W, et al. Cancer Lett. 2022 Oct 1;545:215816. doi: 10.1016/j.canlet.2022.215816. Epub 2022 Jul 8. Cancer Lett. 2022. PMID: 35810989 Review.
Compared with conventional chemotherapy and targeted therapy, immunotherapy has changed the treatment prospects of various solid tumors and has recently become the main treatment method for metastatic or recurrent solid tumors, including malignant melanoma, non-smal …
Compared with conventional chemotherapy and targeted therapy, immunotherapy has changed the treatment prospects of various solid tumors and …
Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines.
Peris K, Fargnoli MC, Garbe C, Kaufmann R, Bastholt L, Seguin NB, Bataille V, Marmol VD, Dummer R, Harwood CA, Hauschild A, Höller C, Haedersdal M, Malvehy J, Middleton MR, Morton CA, Nagore E, Stratigos AJ, Szeimies RM, Tagliaferri L, Trakatelli M, Zalaudek I, Eggermont A, Grob JJ; European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organization for Research and Treatment of Cancer (EORTC). Peris K, et al. Eur J Cancer. 2019 Sep;118:10-34. doi: 10.1016/j.ejca.2019.06.003. Epub 2019 Jul 6. Eur J Cancer. 2019. PMID: 31288208 Review.
Basal cell carcinoma (BCC) is the most common malignant tumour in white populations. Multidisciplinary experts from the European Dermatology Forum, the European Association of Dermato-Oncology and the European Organization of Research and Treatment of Cancer collaborated t …
Basal cell carcinoma (BCC) is the most common malignant tumour in white populations. Multidisciplinary experts from the European Derm …
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.
Long GV, Hauschild A, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Schachter J, Schadendorf D, Lesimple T, Plummer R, Ji R, Zhang P, Mookerjee B, Legos J, Kefford R, Dummer R, Kirkwood JM. Long GV, et al. N Engl J Med. 2017 Nov 9;377(19):1813-1823. doi: 10.1056/NEJMoa1708539. Epub 2017 Sep 10. N Engl J Med. 2017. PMID: 28891408 Free article. Clinical Trial.
BACKGROUND: Combination therapy with the BRAF inhibitor dabrafenib plus the MEK inhibitor trametinib improved survival in patients with advanced melanoma with BRAF V600 mutations. We sought to determine whether adjuvant dabrafenib plus trametinib would improve outco …
BACKGROUND: Combination therapy with the BRAF inhibitor dabrafenib plus the MEK inhibitor trametinib improved survival in patients with a …
Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma.
Baggi A, Quaglino P, Rubatto M, Depenni R, Guida M, Ascierto PA, Trojaniello C, Queirolo P, Saponara M, Peris K, Spagnolo F, Bianchi L, De Galitiis F, Potenza MC, Proietti I, Marconcini R, Botticelli A, Barbieri V, Licitra L, Alfieri S, Ficorella C, Cortellini A, Fargnoli MC, Troiani T, Tondulli L, Bossi P. Baggi A, et al. Eur J Cancer. 2021 Nov;157:250-258. doi: 10.1016/j.ejca.2021.08.018. Epub 2021 Sep 15. Eur J Cancer. 2021. PMID: 34536948
BACKGROUND: Cutaneous squamous cell carcinoma (cSCC) has an overall favourable outcome, except for patients with an advanced stage disease. ...METHODS: This is a retrospective, observational, multicentre study. We analysed medical records of patients with …
BACKGROUND: Cutaneous squamous cell carcinoma (cSCC) has an overall favourable outcome, except for patients with an advanced s …
Uveal melanoma: relatively rare but deadly cancer.
Kaliki S, Shields CL. Kaliki S, et al. Eye (Lond). 2017 Feb;31(2):241-257. doi: 10.1038/eye.2016.275. Epub 2016 Dec 2. Eye (Lond). 2017. PMID: 27911450 Free PMC article. Review.
The alternative to radiation is enucleation. Although these therapies achieve satisfactory local disease control, long-term survival rate for patients with uveal melanoma remains guarded, with risk for liver metastasis. ...As in many other cancer indications, both e …
The alternative to radiation is enucleation. Although these therapies achieve satisfactory local disease control, long-term survival …
Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.
Larkin J, Ascierto PA, Dréno B, Atkinson V, Liszkay G, Maio M, Mandalà M, Demidov L, Stroyakovskiy D, Thomas L, de la Cruz-Merino L, Dutriaux C, Garbe C, Sovak MA, Chang I, Choong N, Hack SP, McArthur GA, Ribas A. Larkin J, et al. N Engl J Med. 2014 Nov 13;371(20):1867-76. doi: 10.1056/NEJMoa1408868. Epub 2014 Sep 29. N Engl J Med. 2014. PMID: 25265494 Free article. Clinical Trial.
BACKGROUND: The combined inhibition of BRAF and MEK is hypothesized to improve clinical outcomes in patients with melanoma by preventing or delaying the onset of resistance observed with BRAF inhibitors alone. ...METHODS: We randomly assigned 495 patients with previ …
BACKGROUND: The combined inhibition of BRAF and MEK is hypothesized to improve clinical outcomes in patients with melanoma by prevent …
Cutaneous melanoma.
Eggermont AM, Spatz A, Robert C. Eggermont AM, et al. Lancet. 2014 Mar 1;383(9919):816-27. doi: 10.1016/S0140-6736(13)60802-8. Epub 2013 Sep 19. Lancet. 2014. PMID: 24054424 Review.
Surgery for localised melanoma and regional lymph node metastases is the standard of care. ...Biomarkers that have predictive value remain elusive in melanoma, although emerging data for adjuvant therapy indicate that interferon sensitivity is associat …
Surgery for localised melanoma and regional lymph node metastases is the standard of care. ...Biomarkers that have predicti …
Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.
Geoerger B, Kang HJ, Yalon-Oren M, Marshall LV, Vezina C, Pappo A, Laetsch TW, Petrilli AS, Ebinger M, Toporski J, Glade-Bender J, Nicholls W, Fox E, DuBois SG, Macy ME, Cohn SL, Pathiraja K, Diede SJ, Ebbinghaus S, Pinto N. Geoerger B, et al. Lancet Oncol. 2020 Jan;21(1):121-133. doi: 10.1016/S1470-2045(19)30671-0. Epub 2019 Dec 4. Lancet Oncol. 2020. PMID: 31812554 Clinical Trial.
BACKGROUND: Pembrolizumab is approved for the treatment of advanced cancer in adults; however, no information is available on safety and efficacy in paediatric patients. ...In this interim analysis, children aged 6 months to 17 years were recruited at 30 hospitals located …
BACKGROUND: Pembrolizumab is approved for the treatment of advanced cancer in adults; however, no information is available on safety …
Chemotherapy for Melanoma.
Wilson MA, Schuchter LM. Wilson MA, et al. Cancer Treat Res. 2016;167:209-29. doi: 10.1007/978-3-319-22539-5_8. Cancer Treat Res. 2016. PMID: 26601864 Review.
Prior to the recent therapeutic advances, chemotherapy was the mainstay of treatment options for advanced-stage melanoma. ...Although new, improved therapeutic options exist for first-line management of advanced-stage melanoma, chemotherapy may …
Prior to the recent therapeutic advances, chemotherapy was the mainstay of treatment options for advanced-stage melanoma …
530 results